Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2022-05-13 Director's Dealing
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-05-13 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 11, 2022, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2022. The text explicitly states that the press release is furnished as an exhibit and that the information is being furnished, not filed, and is not incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of such information. The length is 3519 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but does not contain the full earnings release or detailed financial data itself.
2022-05-11 English
FORM 10-Q
Interim / Quarterly Report Q1 2022
2022-05-11 English
FORM 4
Director's Dealing
2022-05-02 English
FORM DEF 14A
Proxy Solicitation & Information Statement
2022-04-27 English
FORM 4
Director's Dealing
2022-04-18 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.